These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics. Fraley ME; Rubino RS; Hoffman WF; Hambaugh SR; Arrington KL; Hungate RW; Bilodeau MT; Tebben AJ; Rutledge RZ; Kendall RL; McFall RC; Huckle WR; Coll KE; Thomas KA Bioorg Med Chem Lett; 2002 Dec; 12(24):3537-41. PubMed ID: 12443771 [TBL] [Abstract][Full Text] [Related]
5. 1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors. Tripathy R; Ghose A; Singh J; Bacon ER; Angeles TS; Yang SX; Albom MS; Aimone LD; Herman JL; Mallamo JP Bioorg Med Chem Lett; 2007 Mar; 17(6):1793-8. PubMed ID: 17239587 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. Potashman MH; Bready J; Coxon A; DeMelfi TM; DiPietro L; Doerr N; Elbaum D; Estrada J; Gallant P; Germain J; Gu Y; Harmange JC; Kaufman SA; Kendall R; Kim JL; Kumar GN; Long AM; Neervannan S; Patel VF; Polverino A; Rose P; Plas Sv; Whittington D; Zanon R; Zhao H J Med Chem; 2007 Sep; 50(18):4351-73. PubMed ID: 17696416 [TBL] [Abstract][Full Text] [Related]
7. Design and structure-activity relationship of heterocyclic analogs of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones as inhibitors of receptor tyrosine kinases. Frazier K; Jazan E; McBride CM; Pecchi S; Renhowe PA; Shafer CM; Taylor C; Bussiere D; He MM; Jansen JM; Lapointe G; Ma S; Vora J; Wiesmann M Bioorg Med Chem Lett; 2006 Apr; 16(8):2247-51. PubMed ID: 16446087 [TBL] [Abstract][Full Text] [Related]
8. Discovery of novel 1,2,3,4-tetrahydroisoquinolines and 3,4-dihydroisoquinoline-1(2H)-ones as potent and selective inhibitors of KDR: synthesis, SAR, and pharmacokinetic properties. Choquette D; Teffera Y; Polverino A; Harmange JC Bioorg Med Chem Lett; 2008 Jul; 18(14):4054-8. PubMed ID: 18573658 [TBL] [Abstract][Full Text] [Related]
9. Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design. Cook BN; Bentzien J; White A; Nemoto PA; Wang J; Man CC; Soleymanzadeh F; Khine HH; Kashem MA; Kugler SZ; Wolak JP; Roth GP; De Lombaert S; Pullen SS; Takahashi H Bioorg Med Chem Lett; 2009 Feb; 19(3):773-7. PubMed ID: 19111460 [TBL] [Abstract][Full Text] [Related]
10. The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase. Bilodeau MT; Rodman LD; McGaughey GB; Coll KE; Koester TJ; Hoffman WF; Hungate RW; Kendall RL; McFall RC; Rickert KW; Rutledge RZ; Thomas KA Bioorg Med Chem Lett; 2004 Jun; 14(11):2941-5. PubMed ID: 15125964 [TBL] [Abstract][Full Text] [Related]
11. Substituted uracil derivatives as potent inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Steinhagen H; Gerisch M; Mittendorf J; Schlemmer KH; Albrecht B Bioorg Med Chem Lett; 2002 Nov; 12(21):3187-90. PubMed ID: 12372530 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and initial SAR studies of 3,6-disubstituted pyrazolo[1,5-a]pyrimidines: a new class of KDR kinase inhibitors. Fraley ME; Hoffman WF; Rubino RS; Hungate RW; Tebben AJ; Rutledge RZ; McFall RC; Huckle WR; Kendall RL; Coll KE; Thomas KA Bioorg Med Chem Lett; 2002 Oct; 12(19):2767-70. PubMed ID: 12217372 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors. Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536 [TBL] [Abstract][Full Text] [Related]
14. Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity. Munchhof MJ; Beebe JS; Casavant JM; Cooper BA; Doty JL; Higdon RC; Hillerman SM; Soderstrom CI; Knauth EA; Marx MA; Rossi AM; Sobolov SB; Sun J Bioorg Med Chem Lett; 2004 Jan; 14(1):21-4. PubMed ID: 14684289 [TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel inhibitors of gelatinase B. Wang X; Choe Y; Craik CS; Ellman JA Bioorg Med Chem Lett; 2002 Aug; 12(16):2201-4. PubMed ID: 12127537 [TBL] [Abstract][Full Text] [Related]
16. Discovery and evaluation of 3-(5-thien-3-ylpyridin-3-yl)-1H-indoles as a novel class of KDR kinase inhibitors. Fraley ME; Arrington KL; Hambaugh SR; Hoffman WF; Cunningham AM; Young MB; Hungate RW; Tebben AJ; Rutledge RZ; Kendall RL; Huckle WR; McFall RC; Coll KE; Thomas KA Bioorg Med Chem Lett; 2003 Sep; 13(18):2973-6. PubMed ID: 12941314 [TBL] [Abstract][Full Text] [Related]
18. Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics. Dang Q; Kasibhatla SR; Xiao W; Liu Y; Dare J; Taplin F; Reddy KR; Scarlato GR; Gibson T; van Poelje PD; Potter SC; Erion MD J Med Chem; 2010 Jan; 53(1):441-51. PubMed ID: 20055427 [TBL] [Abstract][Full Text] [Related]
19. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. Gingrich DE; Reddy DR; Iqbal MA; Singh J; Aimone LD; Angeles TS; Albom M; Yang S; Ator MA; Meyer SL; Robinson C; Ruggeri BA; Dionne CA; Vaught JL; Mallamo JP; Hudkins RL J Med Chem; 2003 Dec; 46(25):5375-88. PubMed ID: 14640546 [TBL] [Abstract][Full Text] [Related]
20. 2,4-disubstituted pyrimidines: a novel class of KDR kinase inhibitors. Manley PJ; Balitza AE; Bilodeau MT; Coll KE; Hartman GD; McFall RC; Rickert KW; Rodman LD; Thomas KA Bioorg Med Chem Lett; 2003 May; 13(10):1673-7. PubMed ID: 12729639 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]